Home > Boards > US OTC > Biotechs >

Oxford BioMedica PLC (OXBDF)

OXBDF RSS Feed 		Add OXBDF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 9/5/2019 10:37:54 AM - Followers: 6 - Board type: Free - Posts Today: 0

Oxford BioMedica PLC (OXBDF) 
 
Trades In UK as (OXB.L)
  
  
Company website

UK company traded on grey's in US
 

 
Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom - Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001
 
Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
 
Management
 
Partnerships 
 
Financial Reports:  http://www.oxfordbiomedica.co.uk/financial-reports/
 
Investor Contacts:  http://www.oxfordbiomedica.co.uk/investor-contacts/
 
 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
 
 
 
 
 
 
OXBDF
Current Price
Volume:
Bid Ask Day's Range
OXBDF Detailed Quote
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#753   Oxford Biomedica (OXB) - Burgeoning bioprocessing revenues marcusl2 09/05/19 10:37:54 AM
#752   Oxford Biomedica is about to clinch new marcusl2 09/05/19 04:16:36 AM
#751   Gene Therapy for Parkinson’s Disease: Preclinical Evaluation of georgejjl 08/31/19 04:17:07 PM
#750   Robert has a proven track record of helping marcusl2 06/25/19 07:38:39 AM
#749   In a cell and gene therapy sweet spot georgejjl 06/04/19 07:54:09 AM
#748   GREAT NEWS!!! georgejjl 05/28/19 08:01:32 PM
#747   https://www.investegate.co.uk/oxford-biomedica-plc--oxb-/rns/strategic-investmen marcusl2 05/28/19 05:03:47 AM
#746   AXOVANT ANNOUNCES DOSING OF FIRST PATIENT IN SECOND georgejjl 04/30/19 07:50:31 PM
#745   Oxford Biomedica To Get Milestone Payment As Axovant georgejjl 04/30/19 07:45:52 PM
#744   Q1 Kymriah (USD 45 million) strong demand continued marcusl2 04/24/19 06:00:04 AM
#743   Marcus, https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148396 georgejjl 04/23/19 09:00:04 PM
#742   Yes well done. marcusl2 04/09/19 05:15:57 PM
#741   Marcus, Again just FYI georgejjl 04/09/19 07:51:54 AM
#740   Marcus, thank you georgejjl 04/08/19 07:32:10 AM
#739   George, https://www.businesswire.com/news/home/20190408005387/en/Alnylam-Regener marcusl2 04/08/19 07:22:03 AM
#738   They are doing well. marcusl2 04/06/19 04:41:54 PM
#737   Look at the recent price history and trading georgejjl 04/04/19 08:04:15 PM
#736   Marcus, Just FYI. georgejjl 04/04/19 07:18:17 PM
#735   Thanks George. https://www.hardmanandco.com/wp-content/uploads/2019/04/OXB-2018- marcusl2 04/02/19 04:47:54 AM
#734   Marcus, Unrelated to OXB. georgejjl 04/01/19 10:43:03 PM
#733   See page 4 through 20 and 34, 35, georgejjl 03/30/19 09:56:25 PM
#732   Kymriah https://www.youtube.com/watch?v=T-JID2-7WQc&fbclid=IwAR2Dk-cimqPVaImCg marcusl2 03/29/19 06:27:08 AM
#731   https://www.abc.net.au/news/2019-03-25/cancer-patient-says-new-therapy-saved-her marcusl2 03/26/19 05:58:48 PM
#730   Oxford Biomedica marcusl2 03/26/19 05:57:32 PM
#729   https://uk.reuters.com/article/us-brammer-bio-m-a-thermo-fisher/thermo-fisher-to marcusl2 03/25/19 05:35:30 AM
#728   Yes George, JD says that more deals are marcusl2 03/16/19 05:24:46 PM
#727   Marcus, Thank you!!! georgejjl 03/15/19 11:05:03 PM
#726   https://seekingalpha.com/article/4248943-oxford-biomedicas-oxbdf-ceo-john-dawson marcusl2 03/15/19 09:40:55 AM
#725   Oxford Biomedica announces R&D collaboration with Microsoft to georgejjl 03/12/19 07:24:26 PM
#724   A MUST READ REGARDING TODAY'S NEWS!!! georgejjl 03/11/19 07:23:07 PM
#723   Data on Parkinson Disease Gene Therapy, AXO-Lenti-PD, Anticipated georgejjl 02/22/19 03:10:17 PM
#722   Dosed second patient in the SUNRISE-PD phase 2 georgejjl 02/22/19 01:10:46 PM
#721   FDA confirmed that studies previously conducted using firs georgejjl 02/12/19 08:12:16 PM
#720   First two patients dosed in SUNRISE-PD phase 2 georgejjl 02/12/19 08:05:01 PM
#719   Could this possibly be a $15 billion deal cfoofme 12/29/18 05:45:29 PM
#718   CAR-T stocks georgejjl 12/26/18 11:31:18 AM
#717   Doubling Down on Gene Therapies, Novartis Buys CellforCure georgejjl 12/22/18 09:47:02 AM
#716   Novartis, still struggling with Kymriah manufacturing, is providing georgejjl 12/18/18 06:56:29 PM
#715   Safety and Efficacy of OXB-202, a Genetically Engineered georgejjl 12/15/18 05:09:10 PM
#714   Oxford BioMedica to capture 25-30% of lentiviral vector marcusl2 12/10/18 03:21:00 PM
#713   (This is VERY interesting) marcusl2 12/10/18 03:20:33 PM
#712   AXOVANT ANNOUNCES FEEDBACK FROM FDA MEETING REGARDING AXO-LENTI-PD georgejjl 12/06/18 10:01:13 PM
#711   Oxford Biomedica PLC Axovant FDA meeting feedback marcusl2 12/06/18 04:07:44 PM
#710   I agree George, but along with a few marcusl2 12/02/18 02:11:02 PM
#709   Novartis could buyout Oxford BioMedica georgejjl 12/01/18 04:40:40 PM
#708   Oxford BioMedica notes the longer-term analyses from pivotal georgejjl 12/01/18 03:27:20 PM
#707   Possible ways forward for Car T 5T4 combinations ? marcusl2 11/25/18 04:59:39 AM
#706   “Any new therapy is going to start in marcusl2 11/25/18 04:12:25 AM
#705   Scott Gottlieb, M.D. marcusl2 11/25/18 04:11:37 AM
#704   Digital tech from Autolus and Oxford BioMedica to marcusl2 11/22/18 11:41:18 AM
PostSubject
© 2019 InvestorsHub.com, Inc.